Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BTH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

BTH Guru Trades in

Q2 2015

BTH Guru Trades in Q2 2015

Mario Gabelli 287,183 sh (+0.27%)
Charles Brandes Sold Out
» More
Q3 2015

BTH Guru Trades in Q3 2015

Jim Simons 26,800 sh (New)
Mario Gabelli 508,400 sh (+77.03%)
» More
Q4 2015

BTH Guru Trades in Q4 2015

Mario Gabelli Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Consumer Packaged Goods » Household & Personal Products  
Compare:AMEX:ACU, NAS:LFVN, NAS:UG, OTCPK:PURE, NAS:NAII, OTCPK:PNAT, NAS:MTEX, NAS:OBCI, OTCPK:BMBPY, NAS:SUMR, NAS:FHCO, AMEX:CAW, OTCPK:SLGD, OTCPK:SWSH, OTCPK:AXHLF, OTCPK:FTCY, OTCPK:MYHI, OTCPK:NUGN, OTCPK:BMXC, OTCPK:SPCO » details
Traded in other countries:BY3N.Germany,
Headquarter Location:USA


Blyth Inc was incorporated on September 9, 1977. The Company is a multi-channel company focused on the direct to consumer market. The Company designs and markets home fragrance products and decorative accessories, as well as weight management products, nutritional supplements and energy drinks. Its products include decorative and functional household products such as candles, accessories, seasonal decorations, household convenience items and personalized gifts; nutritional supplements such as meal replacement shakes, vitamins and energy mixes; as well as products for the foodservice trade. Its products can be found throughout North America, Europe and Australia. The Company has three business segments the Health and Wellness segment, the Candles and Home Decor segment and the Catalog and Internet segment. Within the Health and Wellness segment, it operates ViSalus, which is sells meal replacement shakes, nutritional supplements, nutritional cookies and energy drinks. Products in this segment are sold through networks of independent sales promoters in the United States and Canada. Within the Candles and Home Decor segment, it designs, manufactures or sources, markets and distributes a line of products including scented candles, candle-related accessories and other fragranced products under the PartyLite brand. PartyLite also offers gourmet foods under the Two Sisters Gourmet by PartyLite brand name. Products in this segment are sold through networks of independent sales consultants. PartyLite brand products are sold in North America, Europe and Australia. Within the Catalog and Internet segment, it designs, sources and markets household convenience items, holiday cards, personalized gifts, kitchen accessories, premium photo albums and frames. These products are sold directly to consumers under the Miles Kimball, Walter Drake, Easy Comforts, As we Change and Exposures brands. These products are sold in North America. Competition in the Candles and Home Decor segment includes companies selling candles manufactured at lower costs through direct selling and retail channels. Competition in the Health and Wellness segment includes companies selling competitive nutritional supplements and weight-loss management products through direct selling and retail channels. In the Health and Wellness and the Candles and Home Decor segments it competes for consultants or promoters with other direct selling companies, both those that sell similar products and those that sell other types of products. The Companys direct selling and network marketing programs are subject to federal and state regulations administered by the FTC and various state agencies as well as regulations in foreign markets administered by foreign agencies.

Top Ranked Articles about Blyth Inc

Breathtec Biomedical Announces Plans for Breath Analysis Clinical Trials at Canadian Tech Facility

City of Surrey's Health &Technology District to Host Breathtec's In-Licensed NA-NOSE Study for Disease Detection

VANCOUVER, BC--(Marketwired - Jun 28, 2016) - Breathtec BioMedical, Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases, is holding a press conference today to announce plans for the commencement of the company's clinical trial program at Innovation Boulevard located in Surrey, British Columbia.  Today's announcement marks the beginning of an intensive research review into NA-NOSE, an advanced stage, nanotechnology-based breath analysis device from the Technion - Israel Institute of Technology which has been in-licensed by Breathtec. The system has been developed to detect the volatile biomarkers of diseases from exhaled breath, and Breathtec has chosen the Province of British Columbia and the City of Surrey to hold its clinical trials for selected respiratory infections at the Health & Technology District on Innovation Boulevard. "Breathtec's exciting technology, developed in Israel, is going through the highest quality clinic trials right here in British Columbia," said Minister of Technology, Innovation and Citizens' Services, Amrik Virk. "We have a vibrant tech sector attracting companies from clean tech, to information and communications systems, to life sciences -- this kind of innovative work is a key part of our diversified economy." "The City of Surrey supports the development of health technologies and we welcome Breathtec Biomedical to our growing stable of health technology specialist firms," said Mayor Linda Hepner. "The addition of Breathtec is another example of how the City of Surrey is committed to working together to help take innovative science and technology ideas off the drawing board and turning them into real working solutions that will improve the quality of life for all." Breathtec CEO Mr. Guy LaTorre states, "We are delighted to come to the City of Surrey, British Columbia and to have the opportunity to access such a world-class facility and team. The NA-NOSE device is an exciting new late stage technology that has already been clinically proven in the early detection of cancer and has the potential to change the way we diagnose respiratory diseases which will be our company's focus."  During the event, NA-NOSE lead researcher Professor Hossam Haick will demonstrate how the nanotechnology-based breath analysis system is used for screening of potentially life-threatening diseases. The licensed technology will be clinically evaluated as a non-invasive point of care device for early detection of community and hospital based infections such as Streptococcus; Methicillin resistant (MRSA); Staphylococcus; Enterococcus; Vancomycin resistant (VRE); Pneumococcus; Hemophilus influenza (HiB); Chickenpox; and the common cold, etc. Press Conference -- Tuesday, June 28th at 11 a.m. (PDT), 2 pm (EDT).

Where: City Centre 1, 13737 96th Avenue, HealthTech Innovation Hub (2nd Floor), Surrey, Canada.

In Attendance:

Honourable Minister Amrik Virk, Minister of Technology, Innovation and Citizens' Services
Mayor Linda Hepner, City of Surrey
Guy LaTorre, Chief Executive Officer, Breathtec Biomedical
Dr. Hossam Haick, Professor in Chemical Engineering and Nanotechnology at Technion -Israel Institute of Technology (product demonstrations)
Dr. Raj Attariwala, MD, PhD., Lead Engineer, Breathtec Biomedical

Innovation Boulevard is an agile partnership of health, business, higher education and government coming together and creating new health technologies to improve peoples' lives through a shared vision to achieve innovative results, improve health outcomes for patients, implement intelligent solutions for the health care economy, attract talented clinicians and researchers, and to grow companies in the health care technology and services sector. Find out more at: www.innovationboulevard.ca. ON BEHALF OF THE BOARD

"Guy LaTorre"

CEO & Director CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.


For further information, please contact:

Kal Malhi

President and Director

Breathtec BioMedical, Inc

http://breathtecbiomedical.com/



or



Core Capital Partners

Telephone: 604-566-9233

Email: [email protected]





Read more...
Breathtec BioMedical Appoints Guy LaTorre as Chief Executive Officer

VANCOUVER, BC--(Marketwired - Jun 20, 2016) - Breathtec BioMedical, Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infections and life threatening diseases, is pleased to announce the appointment of Mr. Guy LaTorre as Chief Executive Officer of the Company. Mr. LaTorre was previously an advisor to the Company on product development and licensing matters. Mr. LaTorre brings over 25 years of experience in the development and commercialization of medical devices and consumer products in a startup company environment. Guy was a co-founder and Vice President of Business Development at Novamin Technology Inc where he was responsible for identifying and managing the Company's relationships with its key clients in the dental products field, including product development of in-office and at-home use products using the company's proprietary ingredient. In that role, he formed and managed product development partnerships between NTI and the leading marketers of professional dental products, including Dentsply Corp, 3M Corp, Sultan Healthcare, Sunstar and others until the company was sold to GlaxoSmithKline (GSK) in 2010 for USD $135 million. Previously, he was the Director of Scientific Affairs at USBiomaterials Corp. which developed and sold synthetic bone grafting products for use in dental, head, neck and orthopedic surgeries. His responsibilities also included product development, manufacturing and business development activities. Prior to USBiomaterials, Mr. LaTorre was the Laboratory Manager of the University of Florida Advanced Materials Research Center where he was responsible for the managed transfer of licensed university technologies to private startup companies. Guy has been the author or co-author of over fifty scientific publications and holds seven US patents with associated filings worldwide. "I am thoroughly delighted to undertake this opportunity with Breathtec during this particularly important period of growth," comments Mr. LaTorre, who further notes, "The Company is nurturing an expanding pipeline of innovative technology during a period of intense interest in the emerging field of breath analysis. The focus here at Breathtec is on early stage, accessible and non-invasive diagnostics across a wide range of diseases. Successful commercialization of this technology is poised to offer a truly profound impact on personal health care delivery. So it's a great pleasure to join with a team that brings such a strong technical and clinical approach to its business." "Speaking on behalf of the Company, we are very pleased to attract an executive of Guy's caliber and particular skill set to join our growing team," notes Mr. Kal Malhi, Breathtec President. "His previous service as a medical device executive focused on building and operating startups, combined with his operational experience in commercializing novel technologies, and in conducting clinical trials to achieve FDA compliance in the medical device sector will be a major asset for Breathtec." Mr. Malhi continues, "I'd also like to take this opportunity to thank Dr. Michael Costanzo for his term of service as outgoing CEO and am delighted to announce his new role as Breathtec's Chief Technology Officer where we are certain his contributions will help guide and propel our clinical and commercialization efforts." ON BEHALF OF THE BOARD

"Kal Malhi"

President & Director CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.


For further information, please contact:

Kal Malhi

President and Director

Breathtec BioMedical, Inc.



or



Core Capital Partners

Telephone: 604-566-9233

Email: [email protected]





Read more...
Breathtec Biomedical Closes License of NA-NOSE Technology for Disease Detection

VANCOUVER, BC--(Marketwired - May 24, 2016) - Breathtec BioMedical, Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases is pleased to announce that further to its press release of April 13, 2016, it has now issued 1,000,000 common shares of the Company ("Shares") to Technion Research and Development Foundation Ltd., an Israeli private company and wholly-owned subsidiary of the Technion -- Israel Institute of Technology ("Technion"), pursuant to a license agreement dated as of March 16, 2016 between the Company and Technion with respect to a non-exclusive license to the NA-Nose technology patents and know-how to enable commercial advancements in the field of infections detection. In addition, further to the Company's press release of April 19, 2016 with respect to the engagement of Professor Hossam Haick of Technion pursuant to a 12 month consulting services agreement, subject to regulatory approval, the Company will issue 60,000 Shares (subject to adjustment in certain circumstances) on or before April 31, 2017 as partial consideration for his services. Shares issued to Technion are subject to a 4 month hold period pursuant to applicable securities laws which expires on September 5, 2016. Shares issued to Professor Hossam Haick will be subject to a 4 month hold period from the date of issuance pursuant to applicable securities laws. Professor Haick is best known for developing the NA-NOSE technology that can be used to detect disease by mechanically "smelling" elements in the breath of potential sufferers. Certain diseases produce chemicals called volatile organic compounds (VOCs), which easily evaporate into the air and produce a discernible scent profile. Haick's Na-NOSE chip detects the unique "signature" of VOCs in exhaled breath. In related news, Professor Dr. Haick has recently been acclaimed as one of the world's most "Good" people, as noted by GOOD Magazine, an international publication that recognizes researchers for the benefits of their work for humanity. According to the magazine publishers, Haick is one of the 100 most influential people in the world who are changing the world in a positive manner. The GOOD 100 are "spearheading change" in the areas of science, education, and business, said the magazine, and Haick, among them, "refuses to accept the existing reality as the end of the story. Not one of the 100 people we have chosen operates out of a desire for fame -- which is precisely why it is important to recognize their activity." Besides the GOOD recognition, Dr. Haick was also recently presented with the Humboldt Research Award, which recognizes top research done throughout the world in cooperation with research institutes in Germany. Awarded by the Alexander von Humboldt Foundation, the prize is given to prominent researchers who have significantly influenced their fields of study in cooperation with research institutes in Germany. It is granted in recognition of a researcher's achievements as a whole -- discoveries, theories, and insights. Mr. Kal Malhi, President of Breathtec Biomedical notes, "We are truly excited by the prospects ahead. This agreement represents a major leap forward in our quest to commercialize the best breath analysis technologies for the detection of disease. Our technical partners are world-class, and with the expert direction of Prof. Haick we are extremely well served. With the close of this agreement we are rapidly moving ahead and arrangements to ship the prototype technology to our research and development team are already underway." For more information, please visit: www.breathtecbiomedical.com. ON BEHALF OF THE BOARD "Kal Malhi"

President & Director CAUTIONARY DISCLAIMER STATEMENT: The applicable securities exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the applicable securities exchange and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.


For further information, please contact:

CORE Capital Partners

Telephone: 604-566-9233

Email: [email protected]

Website: www.breathtecbiomedical.com





Read more...
Breathtec Biomedical Announces Trading on OTCQB

Company Now Fully Reporting on OTC Markets in America, and Continues Trading in Canada (CSE) and in Frankfurt (FRANKFURT)

VANCOUVER, BC--(Marketwired - May 19, 2016) - Breathtec Biomedical, Inc. (CNSX: BTH) (CSE: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases is pleased to announce that its common shares are now trading on the OTCQB® Venture Market in the United States under the symbol "BTHCF." "Breathtec has received international attention regarding our innovative breath testing technologies and recent NA-NOSE technology partnership with the Technion - Israel Institute of Technology. With today's announcement we have also significantly increased our international visibility in the capital markets," said Mr. Kal Malhi, President of Breathtec Biomedical. "This is a major step forward as it positions the Company on a proven trading platform with access to a broad segment of the American investment community which builds upon our current exposure to Canadian and European markets. As a result, we are moving ahead and rapidly furthering development of our novel technologies in readiness for what we perceive is a global marketplace opportunity." The OTCQB Venture Market is for entrepreneurial and development stage U.S. and international companies. To be eligible, companies must be current in their financial reporting, pass a minimum bid price test and undergo an annual company verification and management certification process. The OTCQB quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors. Breathtec Biomedical, Inc. will continue to trade on the Canadian Securities Exchange under its existing symbol CSE: BTH, and on the Frankfurt exchange as XFRA: BTI. For more information, please visit: www.breathtecbiomedical.com. ON BEHALF OF THE BOARD "Kal Malhi"

President & Director CAUTIONARY DISCLAIMER STATEMENT: The applicable Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the applicable Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.


For further information, please contact:

CORE Capital Partners

Telephone: 604-566-9233

Email: [email protected]

Website: www.breathtecbiomedical.com




Read more...

Ratios

vs
industry
vs
history

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.85
BTH's Dividend Yield % is ranked lower than
83% of the 1628 Companies
in the Global Household & Personal Products industry.

( Industry Median: 1.81 vs. BTH: 0.85 )
Ranked among companies with meaningful Dividend Yield % only.
BTH' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.85
Current: 0.85
0
0.85
5-Year Yield-on-Cost % 0.85
BTH's 5-Year Yield-on-Cost % is ranked lower than
83% of the 2022 Companies
in the Global Household & Personal Products industry.

( Industry Median: 2.27 vs. BTH: 0.85 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BTH' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.85
Current: 0.85
0
0.85

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $459.3
EPS (TTM) $ 4.49
Short Percentage of Float0.65%
52-Week Range $2.72 - 10.37
Shares Outstanding (Mil)16.14
» More Articles for BTH

Headlines

Articles On GuruFocus.com
Breathtec Biomedical Announces Plans for Breath Analysis Clinical Trials at Canadian Tech Facility Jun 28 2016 
Breathtec BioMedical Appoints Guy LaTorre as Chief Executive Officer Jun 20 2016 
Breathtec Biomedical Closes License of NA-NOSE Technology for Disease Detection May 24 2016 
Breathtec Biomedical Announces Trading on OTCQB May 19 2016 
Breathtec Biomedical Announces Prof. Hossam Haick as Consultant Apr 19 2016 
Breathtec Biomedical In-Licenses Advanced Stage Breath Analysis Technology Apr 13 2016 
Breathtec Biomedical Provides Update on Lead Project and In-Licensing Discussions Apr 04 2016 
Breathtec Biomedical Appoints Experienced Product Development and Regulatory Consultant Feb 22 2016 
UPDATE - Breathtec Biomedical Commences Trading on the Canadian Securities Exchange (CSE: BTH) Feb 01 2016 
Breathtec Biomedical Commences Trading on the Canadian Securities Exchange (CSE: BTH) Feb 01 2016 

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)